Ash A. Alizadeh

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figures S1-S30 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

  2026-06-17

• Data from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

  2026-06-17

• Supplementary Figures S1-S30 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

  2026-06-17

• Supplementary Tables 1-16 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

  2026-06-17

• Supplementary Tables 1-16 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

  2026-06-17

• Spatial and multi‐omic profiling reveals pericyte‐derived CCL19 as a key prognostic factor in CNS lymphoma

  HemaSphere · 2026-06-01

• Knowledge Graph Modulated Deep Learning for Limited-Sample Clinical Data Analysis

  arXiv (Cornell University) · 2026-05-22

• Knowledge Graph Modulated Deep Learning for Limited-Sample Clinical Data AnalysisPreprint

  arXiv (Cornell University) · 2026-05-22

• Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

  Journal of Clinical Oncology · 2026-04-27

• Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

  Journal of Clinical Oncology · 2025-12-12 · 6 citations

• Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

  2025-12-11

• Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

  2025-12-11

• Optimizing First-Line Therapy for Diffuse Large B-Cell Lymphoma

  Journal of the National Comprehensive Cancer Network · 2025-11-26 · 1 citations

• Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial

  Blood · 2025-11-03

• Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling

  Blood · 2025-11-03

• Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas

  Blood · 2025-11-03

• Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

  Blood · 2025-11-03

• Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma

  Blood · 2025-11-03

• Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

  Blood · 2025-11-03 · 2 citations

• Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

  Blood · 2025-11-03